If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

J Gen Intern Med. 2018 Aug;33(8):1213-1214. doi: 10.1007/s11606-018-4498-3. Epub 2018 Jun 4.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Acute Coronary Syndrome*
  • Cholesterol, LDL
  • Ezetimibe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Simvastatin

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin
  • Ezetimibe